These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28723710)

  • 1. Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.
    Price JC; Dodge JL; Ma Y; Scherzer R; Korn N; Tillinghast K; Peters MG; Noworolski S; Tien PC
    AIDS; 2017 Sep; 31(15):2119-2125. PubMed ID: 28723710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled attenuation parameter accurately detects liver steatosis in people with HIV.
    Duarte M; Tien P; Ma Y; Noworolski SM; Korn N; Price JC
    AIDS; 2022 Dec; 36(15):2147-2152. PubMed ID: 35950941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy.
    Ghotb A; Noworolski SM; Madden E; Scherzer R; Qayyum A; Pannell J; Ferrell L; Peters M; Tien PC
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):228-31. PubMed ID: 20512045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography.
    Recio E; Cifuentes C; Macías J; Mira JA; Parra-Sánchez M; Rivero-Juárez A; Almeida C; Pineda JA; Neukam K
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):905-11. PubMed ID: 23459105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy and Optimal Cut-off of Controlled Attenuation Parameter for the Detection of Hepatic Steatosis in Indian Population.
    Kuchay MS; Choudhary NS; Sharma D; Krishan S; Mishra SK; Wasir JS; Singh MK; Saraf N; Dhampalwar S; Sud R
    J Clin Exp Hepatol; 2022; 12(3):893-898. PubMed ID: 35677514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.
    Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T
    AIDS Patient Care STDS; 2019 May; 33(5):197-206. PubMed ID: 31067123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection.
    Fernandez-Fuertes M; Macías J; Corma-Gómez A; Rincón P; Merchante N; Gómez-Mateos J; Pineda JA; Real LM
    Sci Rep; 2020 Apr; 10(1):6736. PubMed ID: 32317646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled attenuation parameter for the detection of hepatic steatosis in patients with chronic hepatitis B.
    Chen J; Wu D; Wang M; Chen E; Bai L; Liu C; Liao J; Tang H
    Infect Dis (Lond); 2016 Sep; 48(9):670-5. PubMed ID: 27241724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.
    Price JC; Ma Y; Scherzer R; Korn N; Tillinghast K; Peters MG; Noworolski SM; Tien PC
    Hepatology; 2017 Mar; 65(3):853-863. PubMed ID: 27981599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study.
    Sulyok M; Makara M; Rupnik Z; Ferenci T; Újhelyi E; Kormos L; Gerlei Z; Szlávik J; Horváth G; Vályi-Nagy I
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):679-85. PubMed ID: 25923943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.
    Mohr R; Boesecke C; Dold L; Schierwagen R; Schwarze-Zander C; Wasmuth JC; Weisensee I; Rockstroh JK; Trebicka J
    Medicine (Baltimore); 2018 Apr; 97(17):e0462. PubMed ID: 29702998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.
    Karlas T; Petroff D; Garnov N; Böhm S; Tenckhoff H; Wittekind C; Wiese M; Schiefke I; Linder N; Schaudinn A; Busse H; Kahn T; Mössner J; Berg T; Tröltzsch M; Keim V; Wiegand J
    PLoS One; 2014; 9(3):e91987. PubMed ID: 24637477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.
    Macías J; Real LM; Rivero-Juárez A; Merchante N; Camacho A; Neukam K; Rivero A; Mancebo M; Pineda JA
    HIV Med; 2016 Nov; 17(10):766-773. PubMed ID: 27028546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
    J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative US fat fraction for noninvasive assessment of hepatic steatosis in suspected metabolic-associated fatty liver disease.
    Yin H; Fan Y; Yu J; Xiong B; Zhou B; Sun Y; Wang L; Zhu Y; Xu H
    Insights Imaging; 2024 Jun; 15(1):159. PubMed ID: 38902550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
    J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study.
    Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Faliva M; Perna S; Perani G; Alessandrino F; Calliada F; Rondanelli M; Filice C;
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):305-12. PubMed ID: 25629575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients.
    Praktiknjo M; Djayadi N; Mohr R; Schierwagen R; Bischoff J; Dold L; Pohlmann A; Schwarze-Zander C; Wasmuth JC; Boesecke C; Rockstroh JK; Trebicka J
    Liver Int; 2019 Aug; 39(8):1514-1520. PubMed ID: 30916873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of intimate correlation between visceral fat and hepatic steatosis: Quantitative measurement techniques using CT for area of fat and MR for hepatic steatosis.
    Choi MH; Choi JI; Park MY; Rha SE; Oh SN; Jung SE; Byun JY; Kannengiesser S; Son Y
    Clin Nutr; 2018 Feb; 37(1):214-222. PubMed ID: 28049553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility based multiparametric quantification of liver disease: Non-invasive evaluation of steatosis and iron overload.
    Uhrig M; Mueller J; Longerich T; Straub BK; Buschle LR; Schlemmer HP; Mueller S; Ziener CH
    Magn Reson Imaging; 2019 Nov; 63():114-122. PubMed ID: 31425813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.